Asheebo Rojas

Asheebo Rojas

Auto-generated profile, based on publicly available information

Asheebo Rojas

Department of Pharmacology, Emory University, 1510 Clifton Road NE, Atlanta, GA 30322, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2013 in Epilepsia
Verified
Journal Article
Open access
PDF file
ARAsheebo Rojas
Asheebo Rojas
JJJianxiong Jiang
Jianxiong Jiang
TGThota Ganesh
Thota Ganesh
MYMyung‐Soon Yang
Myung‐Soon Yang
NLNadia Lelutiu
Nadia Lelutiu
RDRaymond Dingledine
Raymond Dingledine
Summary: Epilepsy is one of the more prevalent neurologic disorders in the world, affecting approximately 50 million people of different ages and backgrounds. Epileptic seizures propagating through both lobes of the forebrain can have permanent debilitating effects on a patient's cognitive and somatosensory brain functions. Epilepsy, defined by the sporadic occurrence of spontaneous recurrent seizures (SRS), is often accompanied by inflammation of the brain. Pronounced increases in the expression of key inflammatory mediators (e.g., interleukin ‐1β [IL‐1β], tumor necrosis factor alpha [TNFα], cyclooxygenase‐2 [COX‐2], and C‐X‐C motif chemokine 10 [CXCL10]) after seizures may cause secondary damage in the brain and increase the likelihood of repetitive seizures. TheCOX‐2 enzyme is induced rapidly during seizures. The increased level ofCOX‐2 in specific areas of the epileptic brain can help to identify regions of seizure‐induced brain inflammation. A good deal of effort has been expended to determine whetherCOX‐2 inhibition might be neuroprotective and represent an adjunct therapeutic strategy along with antiepileptic drugs used to treat epilepsy. However, the effectiveness ofCOX‐2 inhibitors on epilepsy animal models appears to depend on the timing of administration. With all of the effort placed on making use ofCOX‐2 inhibitors as therapeutic agents for the treatment of epilepsy, inflammation, and neurodegenerative diseases there has yet to be a selective and potentCOX‐2 inhibitor that has shown a clear therapeutic outcome with acceptable side effects.

1 June 2015 in Neuropharmacology
Verified
Journal Article
Closed access
ARAsheebo Rojas
Asheebo Rojas
TGThota Ganesh
Thota Ganesh
NLNadia Lelutiu
Nadia Lelutiu
PGPaoula Gueorguieva
Paoula Gueorguieva
RDRaymond Dingledine
Raymond Dingledine

1 November 2016 in Neuropharmacology
Verified
Journal Article
Closed access
ARAsheebo Rojas
Asheebo Rojas
TGThota Ganesh
Thota Ganesh
ZMZahra Manji
Zahra Manji
TOTheon O'NEill
Theon O'NEill
RDRaymond Dingledine
Raymond Dingledine

16 January 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RARadhika Amaradhi
Radhika Amaradhi
ABAvijit Banik
Avijit Banik
SMSHABBER MOHAMMED
SHABBER MOHAMMED
VPVidyavathi Patro
Vidyavathi Patro
ARAsheebo Rojas
Asheebo Rojas
TGThota Ganesh
Thota Ganesh

1 October 2014 in Neurobiology of Disease
Verified
Journal Article
Closed access
ARAsheebo Rojas
Asheebo Rojas
PGPaoula Gueorguieva
Paoula Gueorguieva
NLNadia Lelutiu
Nadia Lelutiu
YQYi Quan
Yi Quan
RSRenee Shaw
Renee Shaw
RDRaymond Dingledine
Raymond Dingledine

1 September 2007 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
ARAsheebo Rojas
Asheebo Rojas
NCNingren Cui
Ningren Cui
JSJunda Su
Junda Su
LYLiang Yang
Liang Yang
JMJean-Pierre Muhumuza
Jean-Pierre Muhumuza
CJChun Jiang
Chun Jiang